HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EFSA Considers Vitamin D Max Levels As Part Of VMS Evidence Review

Executive Summary

Vitamin D is one of eight micronutrients being reviewed by the European Food Safety Authority in terms of tolerable upper intake levels (ULs).

You may also be interested in...



EU Selenium Supplement Users Risk Exceeding EFSA’s Proposed Intake Limit For Mineral

The European Food Safety Authority is recommending lowering the tolerable upper intake level for selenium from 300 μg/day to 255 μg/day. Regular users of high-dose selenium supplements could potentially breach this new limit, which has been set to reduce the risk of adverse health effects.

Vitamin D Supplements And COVID-19: Still No Evidence, No Harm In Doing It Anyway

Two new RCTs cast further doubt on the preventative effects of vitamin D supplementation with regards to COVID-19 infection. Nevertheless, an editorial in the British Medical Journal, where the studies were published, leaves open positive effects for those suffering from vitamin D deficiency, and recommends a daily supplement of up to 2000IU just in case.

No OTC High Dose Vit D3 Supplements, Say German Doctors After Infant Overdose Case

The Drug Commission of the German Medical Association warns against the unsupervised use of high-dose vitamin D3 supplements after the overdose of a seven-month-old German infant.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151693

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel